Aflatoxin as a human carcinogen
G. Wogan
DOI: https://doi.org/10.1002/HEP.510300231
IF: 17.298
1999-08-01
Hepatology
Abstract:In this issue of HEPATOLOGY, Sun et al.1 describe a study in which a cohort of 145 men with chronic hepatitis B virus (HBV) in Qidong, Jiangsu Province, China, were followed prospectively for a period of 10 years to determine whether exposure to aflatoxin, concomitant infection with hepatitis C virus (HCV), or other factors increased the risk of hepatocellular carcinoma (HCC) development. Aflatoxin exposure over an 8-month period preceding follow-up, assessed by measurement of the aflatoxin metabolite M1 in pooled monthly urine samples, increased the relative risk (RR) for HCC by 3.3-fold. The authors concluded that aflatoxin exposure can account for a substantial part of the risk of HCC in men with chronic HBV. HCV infection also increased RR by 5.8-fold, showing that the 2 hepatitis viruses interact as risk factors for HCC. These findings complement and extend the findings of earlier studies in general populations, strengthening the conclusion that aflatoxin is a causative agent for HCC and substantially amplifies the risk created by HBV infection. It is now well established that chronic infections by HBV and HCV are major risk factors for the great majority of HCC cases worldwide.2 They also are largely responsible for the geographical pattern of HCC incidence, with HBV being the dominant cause in developing countries of subSaharan Africa and Asia, whereas HCV is the major risk factor in developed countries with a high or intermediate incidence. Evidence supporting these conclusions was recently summarized by Kew.3 Carrier rates of HBV in African and Asian populations may be as high as 20%, and the infection is acquired early in life as a result either of perinatal infection by a carrier mother or by horizontal passage from infectious siblings. Males acquiring carrier status early in life are at very high risk of developing HCC, with a lifetime RR of 100 calculated for Taiwanese carriers. Thus, chronic infection with HBV has been stated to be the single most common cause of global HCC.3 The importance of HCV infection in the causation of HCC has been recognized more recently, and interactive effects between the carcinogenicity of HBV and HCV have been shown in most, but not all, populations in which it has been studied. Mechanisms through which these infections cause HCC are still unknown, although both direct and indirect actions are thought to be involved. The potency of HBV infection as a cause of HCC delayed recognition of the significance of aflatoxin exposure, evidence of which has mounted over a period of several decades. Aflatoxins belong to a large group of toxic metabolites that contaminate food and feed commodities during growth of certain specific spoilage molds. In addition to causing acute toxicity, aflatoxins are also liver carcinogens in experimental animals. They frequently contaminate major foodstuffs, necessitating extensive quality control measures to minimize levels in finished products. Continuing research efforts stimulated by their discovery in the early 1960s have produced an extensive body of evidence regarding human health risks resulting from aflatoxin exposure. Collectively, epidemiological data together with evidence from many types of experimental models define the role of aflatoxin exposure in HCC causation, and it is informative to review this information for perspective regarding the multifactorial etiology of the disease. Aflatoxin-contaminated feed was discovered to be a liver carcinogen in rats even before the active agent was isolated and characterized. Subsequent experiments with chemically pure toxin showed that HCC was induced in sensitive species when aflatoxin B1 (AFB1), the major component of mixtures typically found in food raw materials, was fed at levels as low as 15 parts per billion (μg/kg) in the diet. Bioassays in various species of fish, birds, rodents, and subhuman primates eventually showed that AFB1 is a liver carcinogen in all animals tested. Although there is wide variation in sensitivity, no completely refractory species has been identified. These data clearly implicate aflatoxin as a potential liver carcinogen in humans, and the plausibility of this implication is supported by much additional experimental evidence.4 Aflatoxin is strongly mutagenic in test systems ranging from bacteria to human cells in culture, requiring metabolic activation by cytochrome P450; pathways of aflatoxin metabolism are similar in cells and tissues of susceptible animals and humans, including the epoxidation pathway resulting in covalent binding to DNA; the DNA adduct profile, with the aflatoxin-N7-guanine adduct (AFB1-N-gua) representing the major adduct, is identical in animal and human cells mutagenized by aflatoxin; adduct level in liver DNA is quantitatively related to aflatoxin dose and to tumor yield; and chemoprevention of DNA adduct formation inhibits tumorigenesis in experimental animals. Early recognition of aflatoxin carcinogenicity together with the high frequency with which it occurs as a food contaminant stimulated cross-sectional epidemiological investigations to determine whether exposure was related to elevated occurrence of HCC. Collectively, studies conducted in subSaharan Africa and Asia between 1965 and 1985 showed a highly significant association between AFB1 intake, calculated from analysis of foods as consumed, and HCC incidence estimated from cancer registry data.5 Based on these epidemiological data, together with the body of experimental evidence outlined previously, AFB1 was designated as a known human Abbreviations: HBV, hepatitis B virus; HCV, hepatitis C virus; HCC, hepatocellular carcinoma; RR, relative risk; AFB1, aflatoxin B1; AFB1-N-gua, aflatoxin B1-N-guanine. From the Division of Bioengineering and Environmental Health, Massachusetts Institute of Technology, Cambridge, MA. Received May 25, 1999; accepted May 28, 1999. Address reprint requests to: Gerald N. Wogan, Ph.D., Division of Bioengineering and Environmental Health, Massachusetts Institute of Technology, 77 Massachusetts Ave., Cambridge, MA 02139. E-mail: wogan@mit.edu; fax: 617-258-9733. Copyright r 1999 by the American Association for the Study of Liver Diseases. 0270-9139/99/3002-0032$3.00/0